Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vera J Suman

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccineStephen M Ansell, Vera J Suman
Lancet (London, England)|August 30, 2008
Lack of publication bias related to results from trastuzumab studyEdith A Perez, Vera J Suman
The Journal of Steroid Biochemistry and Molecular Biology|June 9, 2005
Aromatase inhibitors for therapy of advanced breast cancerJames N Ingle, Vera J Suman
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settingsJames N Ingle, Vera J Suman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast CancerMatthew P Goetz, Vera J Suman
Cancer Investigation|June 24, 2008
Clinical trials of novel and targeted therapies: endpoints, trial design, and analysisVera J Suman, Amylou Dueck, Daniel J Sargent
Leukemia|January 13, 2019
Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter GaleSarah A Holstein, Vera J Suman, Philip L McCarthy
Therapeutic Advances in Medical Oncology|December 14, 2019
The emerging role of CDK4/6i in HER2-positive breast cancerCiara C O'Sullivan, Vera J Suman, Matthew P Goetz
Therapeutic Advances in Hematology|July 18, 2018
Update on the role of lenalidomide in patients with multiple myelomaSarah A Holstein, Vera J Suman, Philip L McCarthy
Current Hematologic Malignancy Reports|January 21, 2019
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?Sarah A Holstein, Vera J Suman, Philip L McCarthy
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccineStephen M Ansell, Vera J Suman
Lancet (London, England)|August 30, 2008
Lack of publication bias related to results from trastuzumab studyEdith A Perez, Vera J Suman
The Journal of Steroid Biochemistry and Molecular Biology|June 9, 2005
Aromatase inhibitors for therapy of advanced breast cancerJames N Ingle, Vera J Suman
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settingsJames N Ingle, Vera J Suman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast CancerMatthew P Goetz, Vera J Suman
Cancer Investigation|June 24, 2008
Clinical trials of novel and targeted therapies: endpoints, trial design, and analysisVera J Suman, Amylou Dueck, Daniel J Sargent
Leukemia|January 13, 2019
Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter GaleSarah A Holstein, Vera J Suman, Philip L McCarthy
Therapeutic Advances in Medical Oncology|December 14, 2019
The emerging role of CDK4/6i in HER2-positive breast cancerCiara C O'Sullivan, Vera J Suman, Matthew P Goetz
Therapeutic Advances in Hematology|July 18, 2018
Update on the role of lenalidomide in patients with multiple myelomaSarah A Holstein, Vera J Suman, Philip L McCarthy
Current Hematologic Malignancy Reports|January 21, 2019
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?Sarah A Holstein, Vera J Suman, Philip L McCarthy
Pageof 15